Last reviewed · How we verify
Placebo + SOC — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo + SOC (Placebo + SOC) — 101 Therapeutics. Placebo combined with standard of care provides a control comparator in clinical trials to assess the incremental benefit of an investigational therapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo + SOC TARGET | Placebo + SOC | 101 Therapeutics | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo + SOC CI watch — RSS
- Placebo + SOC CI watch — Atom
- Placebo + SOC CI watch — JSON
- Placebo + SOC alone — RSS
Cite this brief
Drug Landscape (2026). Placebo + SOC — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-soc. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing